These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 23278847)

  • 1. Some implications of receptor kinase signaling pathway for development of multitargeted kinase inhibitors.
    Mitrasinovic PM
    Curr Radiopharm; 2013 Mar; 6(1):48-55. PubMed ID: 23278847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidermal growth factor receptors: a functional perspective.
    Mitrasinovic PM
    Curr Radiopharm; 2012 Jan; 5(1):29-33. PubMed ID: 22074479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular imaging of EGFR kinase activity in tumors with 124I-labeled small molecular tracer and positron emission tomography.
    Pal A; Glekas A; Doubrovin M; Balatoni J; Namavari M; Beresten T; Maxwell D; Soghomonyan S; Shavrin A; Ageyeva L; Finn R; Larson SM; Bornmann W; Gelovani JG
    Mol Imaging Biol; 2006; 8(5):262-77. PubMed ID: 16897320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular imaging of epidermal growth factor receptor expression-activity at the kinase level in tumors with positron emission tomography.
    Gelovani JG
    Cancer Metastasis Rev; 2008 Dec; 27(4):645-53. PubMed ID: 18626573
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imaging of EGFR and EGFR tyrosine kinase overexpression in tumors by nuclear medicine modalities.
    Mishani E; Abourbeh G; Eiblmaier M; Anderson CJ
    Curr Pharm Des; 2008; 14(28):2983-98. PubMed ID: 18991714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
    Roskoski R
    Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imaging EGFR and HER2 by PET and SPECT: a review.
    Corcoran EB; Hanson RN
    Med Res Rev; 2014 May; 34(3):596-643. PubMed ID: 24037872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imaging of human epidermal growth factor receptors for patient selection and response monitoring - From PET imaging and beyond.
    Pereira PMR; Abma L; Henry KE; Lewis JS
    Cancer Lett; 2018 Apr; 419():139-151. PubMed ID: 29414302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimizing tumor targeting of the lipophilic EGFR-binding radiotracer SKI 243 using a liposomal nanoparticle delivery system.
    Medina OP; Pillarsetty N; Glekas A; Punzalan B; Longo V; Gönen M; Zanzonico P; Smith-Jones P; Larson SM
    J Control Release; 2011 Feb; 149(3):292-8. PubMed ID: 21047536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PET and SPECT Imaging of the EGFR Family (RTK Class I) in Oncology.
    Rinne SS; Orlova A; Tolmachev V
    Int J Mol Sci; 2021 Apr; 22(7):. PubMed ID: 33915894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progress in structure-based design of EGFR inhibitors.
    Mitrasinovic PM
    Curr Drug Targets; 2013 Jun; 14(7):817-29. PubMed ID: 23547755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis of [64Cu]Cu-NOTA-Bn-GE11 for PET imaging of EGFR-rich tumors.
    Dejesus OT
    Curr Radiopharm; 2012 Jan; 5(1):15-8. PubMed ID: 21864245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PET Imaging of Receptor Tyrosine Kinases in Cancer.
    Wei W; Ni D; Ehlerding EB; Luo QY; Cai W
    Mol Cancer Ther; 2018 Aug; 17(8):1625-1636. PubMed ID: 30068751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Experimental results and related clinical implications of PET detection of epidermal growth factor receptor (EGFr) in cancer.
    Pantaleo MA; Nannini M; Maleddu A; Fanti S; Nanni C; Boschi S; Lodi F; Nicoletti G; Landuzzi L; Lollini PL; Biasco G
    Ann Oncol; 2009 Feb; 20(2):213-26. PubMed ID: 18842614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular imaging of breast cancer.
    Oude Munnink TH; Nagengast WB; Brouwers AH; Schröder CP; Hospers GA; Lub-de Hooge MN; van der Wall E; van Diest PJ; de Vries EG
    Breast; 2009 Oct; 18 Suppl 3():S66-73. PubMed ID: 19914546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A tyrosine kinase inhibitor-based high-affinity PET radiopharmaceutical targets vascular endothelial growth factor receptor.
    Li F; Jiang S; Zu Y; Lee DY; Li Z
    J Nucl Med; 2014 Sep; 55(9):1525-31. PubMed ID: 24970912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiohalogenated nonnatural amino acids as PET and SPECT tumor imaging agents.
    McConathy J; Yu W; Jarkas N; Seo W; Schuster DM; Goodman MM
    Med Res Rev; 2012 Jul; 32(4):868-905. PubMed ID: 21793016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Irreversible multitargeted ErbB family inhibitors for therapy of lung and breast cancer.
    Subramaniam D; He AR; Hwang J; Deeken J; Pishvaian M; Hartley ML; Marshall JL
    Curr Cancer Drug Targets; 2015; 14(9):775-93. PubMed ID: 25435079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidermal growth factor receptor dependence in human tumors: more than just expression?
    Arteaga CL
    Oncologist; 2002; 7 Suppl 4():31-9. PubMed ID: 12202786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: molecular bases for EGFR-targeted therapy.
    Uribe P; Gonzalez S
    Pathol Res Pract; 2011 Jun; 207(6):337-42. PubMed ID: 21531084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.